PMID- 15307183
OWN - NLM
STAT- MEDLINE
DCOM- 20041007
LR  - 20041117
IS  - 0014-2980 (Print)
IS  - 0014-2980 (Linking)
VI  - 34
IP  - 9
DP  - 2004 Sep
TI  - Potent T cell response to a class I-binding 13-mer viral epitope and the 
      influence of HLA micropolymorphism in controlling epitope length.
PG  - 2510-9
AB  - The BZLF1 antigen of Epstein-Barr virus includes three overlapping sequences of 
      different lengths that conform to the binding motif of human leukocyte antigen 
      (HLA) B*3501. These 9-mer (56LPQGQLTAY64), 11-mer (54EPLPQGQLTAY64), and 13-mer 
      (52LPEPLPQGQLTAY64) peptides all bound well to B*3501; however, the CTL response 
      in individuals expressing this HLA allele was directed strongly and exclusively 
      towards the 11-mer peptide. In contrast, EBV-exposed donors expressing HLA B*3503 
      showed no significant CTL response to these peptides because the single amino 
      acid difference between B*3501 and B*3503 within the F pocket inhibited HLA 
      binding by these peptides. The extraordinarily long 13-mer peptide was the target 
      for the CTL response in individuals expressing B*3508, which differs from B*3501 
      at a single position within the D pocket (B*3501, 156Leucine; B*3508, 
      156Arginine). This minor difference was shown to enhance binding of the 13-mer 
      peptide, presumably through a stabilizing interaction between the negatively 
      charged glutamate at position 3 of the peptide and the positively charged 
      arginine at HLA position 156. The 13-mer epitope defined in this study represents 
      the longest class I-binding viral epitope identified to date as a minimal 
      determinant. Furthermore, the potency of the response indicates that peptides of 
      this length do not present a major structural barrier to CTL recognition.
CI  - Copyright 2004 Wiley-VCH Verlag GmbH & Co.
FAU - Green, Kate J
AU  - Green KJ
AD  - Division of Infectious Diseases and Immunology, Queensland Institute of Medical 
      Research, Brisbane, Australia.
FAU - Miles, John J
AU  - Miles JJ
FAU - Tellam, Judy
AU  - Tellam J
FAU - van Zuylen, Wendy J M
AU  - van Zuylen WJ
FAU - Connolly, Geoff
AU  - Connolly G
FAU - Burrows, Scott R
AU  - Burrows SR
LA  - eng
PT  - Journal Article
PL  - Germany
TA  - Eur J Immunol
JT  - European journal of immunology
JID - 1273201
RN  - 0 (BZLF1 protein, Herpesvirus 4, Human)
RN  - 0 (DNA-Binding Proteins)
RN  - 0 (Epitopes, T-Lymphocyte)
RN  - 0 (HLA-B35 Antigen)
RN  - 0 (Immunodominant Epitopes)
RN  - 0 (Peptide Fragments)
RN  - 0 (Trans-Activators)
RN  - 0 (Viral Proteins)
SB  - IM
MH  - Antigen Presentation
MH  - Cell Line
MH  - DNA-Binding Proteins/immunology
MH  - *Epitopes, T-Lymphocyte
MH  - HLA-B35 Antigen/*metabolism
MH  - Herpesvirus 4, Human/*immunology
MH  - Humans
MH  - Immunodominant Epitopes
MH  - Peptide Fragments/*metabolism
MH  - Polymorphism, Genetic
MH  - T-Lymphocytes/*immunology
MH  - T-Lymphocytes, Cytotoxic/*immunology
MH  - Trans-Activators/immunology
MH  - Viral Proteins/immunology
EDAT- 2004/08/13 05:00
MHDA- 2004/10/08 09:00
CRDT- 2004/08/13 05:00
PHST- 2004/08/13 05:00 [pubmed]
PHST- 2004/10/08 09:00 [medline]
PHST- 2004/08/13 05:00 [entrez]
AID - 10.1002/eji.200425193 [doi]
PST - ppublish
SO  - Eur J Immunol. 2004 Sep;34(9):2510-9. doi: 10.1002/eji.200425193.